menu
    • menu
    [{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Enzyme","year":"2023","type":"Collaboration","leadProduct":"Anacaulase","moa":"Alpha-1-antichymotrypsin; Alpha-2-macroglobulin||Peptide hydrolase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Molnlycke Health Care AB \/ MediWound","highestDevelopmentStatusID":"8","companyTruncated":"Molnlycke Health Care AB \/ MediWound"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ Undisclosed"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"BioScience Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Chlorhexidine Gluconate","moa":"Cell membrane","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molnlycke Health Care AB \/ BioScience Laboratories","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ BioScience Laboratories"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Molnlycke Health Care AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Silver Sulfate","moa":"Immune","graph1":"Dermatology","graph2":"Phase IV","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Molnlycke Health Care AB \/ Molnlycke Health Care AB","highestDevelopmentStatusID":"11","companyTruncated":"Molnlycke Health Care AB \/ Molnlycke Health Care AB"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"SWEDEN","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Mepilex AG","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Undisclosed","graph3":"Molnlycke Health Care AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Molnlycke Health Care AB \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Molnlycke Health Care AB \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Molnlycke Health Care AB

    Menu

    Molnlycke Health Care AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Anacaulase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : MediWound

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

                            Details : Under the collaboration, Mölnlycke will provide Mepilex® Up, its most recent line extension to its global market leading brand, along with Exufiber® and Exufiber® Ag dressings to be used during MediWound's upcoming Phase III study of EscharEx (EX-02)...

                            Product Name : EscharEx

                            Product Type : Enzyme

                            Upfront Cash : Undisclosed

                            August 15, 2023

                            Lead Product(s) : Bromelain Enriched Proteolytic Enzyme,Anacaulase

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : MediWound

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : BioScience Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A 96-hour Patch Test Study Using Healthy Human Volunteers to Assess the Skin Irritation Potential of 11 Topica...

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 28, 2021

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : BioScience Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : BioScience Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-1...

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 04, 2020

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : BioScience Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application T...

                            Details : Chlorhexidine Gluconate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 22, 2020

                            Lead Product(s) : Chlorhexidine Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Silver Sulfate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Recipient : University Hospital, Clermont-Ferrand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on Pressure Ulcers Prevention With Mepilex® Border Sacrum Dressing in Scheduled Cardiovascular Surger...

                            Details : Mepilex Border Dressing (Silver Sulfate) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pressure Ulcer.

                            Product Name : Mepilex Border Dressing

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2019

                            Lead Product(s) : Silver Sulfate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Recipient : University Hospital, Clermont-Ferrand

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Molnlycke Health Care AB

                            Sweden arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mepilex AG

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.

                            Details : Mepilex AG is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Burns.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 22, 2011

                            Lead Product(s) : Mepilex AG

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth